• In late April 2026, Phathom Pharmaceuticals reported that its first-quarter net loss narrowed to US$30.37 million from US$94.32 million a year earlier, while maintaining full-year 2026 net revenue guidance of US$320 million to US$345 million and expecting operating profitability, excluding stock-based compensation, to begin in the third quarter of 2026.
• The company also disclosed a change in how it classifies certain third-party costs starting January 1, 2026, which could make future margins and cost trends easier for investors to interpret.
• We’ll now examine how the reaffirmed 2026 profitability timeline may influence Phathom’s investment narrative and expectations around VOQUEZNA’s growth.

The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Phathom Pharmaceuticals Investment Narrative Recap

To own Phathom, you need to believe VOQUEZNA can justify a focused, single-product story long enough for the company to reach and sustain profitability. The Q1 2026 results and reaffirmed 2026 guidance support the near term profitability catalyst but do not remove the key risk that so much value is tied to one drug in one market.

The most relevant update here is the reaffirmed 2026 outlook, including expected operating profitability (excluding stock based compensation) beginning in the third quarter of 2026. Along with the narrower Q1 loss, this keeps the near term profitability timeline intact and may help investors better interpret future margins as the new cost classification flows through reported results.

Yet behind the improving loss line, investors should still be aware of how heavily everything depends on VOQUEZNA and what happens if...

Phathom Pharmaceuticals’ narrative projects $792.0 million revenue and $288.7 million earnings by 2029.

Uncover how Phathom Pharmaceuticals' forecasts yield a $23.70 fair value, a 93% upside to its current price.

Exploring Other Perspectives

Before this update, the most pessimistic analysts were still assuming rapid growth, with revenue reaching about US$651.4 million by 2029, yet they warned that heavy reliance on a narrow GI pipeline could make that path far bumpier than consensus expects, so it is worth weighing how this new profitability guidance might shift both the optimistic and cautious views.

Explore 2 other fair value estimates on Phathom Pharmaceuticals - why the stock might be a potential multi-bagger!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Phathom Pharmaceuticals research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Phathom Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Phathom Pharmaceuticals' overall financial health at a glance.

Looking For Alternative Opportunities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.